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Abstract
Background: Less than 20 % of familial breast cancer patients who undergo genetic testing for BRCA1 and BRCA2
carry a pathogenic mutation in one of these two genes. The GENESIS (GENE SISter) study was designed to identify
new breast cancer susceptibility genes in women attending cancer genetics clinics and with no BRCA1/2 mutation.
Methods: The study involved the French national network of family cancer clinics. It was based on enrichment in
genetic factors of the recruited population through case selection relying on familial criteria, but also on the
consideration of environmental factors and endophenotypes like mammary density or tumor characteristics to
assess potential genetic heterogeneity. One of the initial aims of GENESIS was to recruit affected sibpairs. Siblings were
eligible when index cases and at least one affected sister were diagnosed with infiltrating mammary or ductal
adenocarcinoma, with no BRCA1/2 mutation. In addition, unrelated controls and unaffected sisters were recruited.
The enrolment of patients, their relatives and their controls, the collection of the clinical, epidemiological, familial
and biological data were centralized by a coordinating center.
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Results: Inclusion of participants started in February 2007 and ended in December 2013. A total of 1721 index
cases, 826 affected sisters, 599 unaffected sisters and 1419 controls were included. 98 % of participants completed the
epidemiological questionnaire, 97 % provided a blood sample, and 76 % were able to provide mammograms. Index
cases were on average 59 years old at inclusion, were born in 1950, and were 49.7 years of age at breast cancer
diagnosis. The mean age at diagnosis of affected sisters was slightly higher (51.4 years). The representativeness of
the control group was verified.
Conclusions: The size of the study, the availability of biological specimens and the clinical data collection together
with the detailed and complete epidemiological questionnaire make this a unique national resource for investigation
of the missing heritability of breast cancer, by taking into account environmental and life style factors and stratifying
data on endophenotypes to decrease genetic heterogeneity.
Background
Less than 20 % of women affected by breast cancer (BC)
and qualified for BRCA1/2 testing are carrying a deleteri-
ous (or pathological) mutation in one of these genes [1].
Mutations in other genes causing familial syndromes in
which BC incidence is highly increased (TP53, PTEN,
STK11 and CDH1) are estimated to cause 5 % of the fa-
milial forms of BC and an additional 5 % is accounted for
by moderate penetrance genes (i.e. associated with an
odds ratio (OR) below 3), such as ATM, CHEK2, and the
Fanconi anemia pathway genes (BRIP1, PALB2, RAD51C,
RAD51D and XRCC2). Therefore, the majority of the fa-
milial forms of BC remain unexplained. Schematically, the
studies performed to elucidate the missing heritability
have either been on high-risk populations using mainly
linkage analysis approaches to detect “major” genes or on
the general population using association studies to detect
“more” common genetic “variations”. Linkage analyses
failed to identify new “major” loci [2] while genome-wide
association studies performed on large case-control stud-
ies of BC have identified about 100 common BC suscepti-
bility loci (single nucleotide polymorphisms or SNPs) to
date (e.g. [3–13]). However, the effect sizes detected by
these large-scale studies were small, for the vast majority,
the associated OR rarely being greater than 1.20, and
altogether may account for only 14 % of the missing herit-
ability [14].
There is likely a genetic heterogeneity, with different
types of predisposing situations observed among women
at risk. These genetic “sub-entities” resulting from the
combination of several factors may be associated with par-
ticular characteristics of the individual or of the tumor.
For example, several SNPs identified by genome-wide as-
sociation studies were shown to be associated with the es-
trogen receptor status of the breast tumor both in the
general population [3, 4, 15–17] and the population of
BRCA2 mutation carriers [18–21].
Our proposal was to set up a study to investigate the
missing heritability of BC in a high-risk population with
unrelated controls for conducting association studies. The
novelty of the GENESIS (GENE SISters) study is the re-
cruitment of a study population enriched in susceptibility
factors by case selection based on familial criteria, with
consideration of environmental factors. Potential genetic
heterogeneity was accounted for by stratifying the study
sample on proxy such as particular individual epidemio-
logical or clinical characteristics (mammary density, for
example), or tumor characteristics.
The GENESIS study is an integrative genetic epidemio-
logical project based on the involvement of all French fam-
ily cancer clinic consultants who belong to the “Groupe
Génétique et Cancer” (GGC) of Unicancer, the centralized
enrolment of patients and collection of their clinical, epi-
demiological, familial and biological data by a coordinating
center (CC) at the Institut Curie (Paris, France). Here we
describe the design and logistics of the study and the avail-
able data. We also discuss the participation rates, the
prevalence of the BC cases, and the representativeness of
the participants and of the population of controls.
Methods
Eligible individuals
Index cases (and their affected sisters) were identified
through the French family cancer clinics of the GGC
(i.e. 42 centers) and were eligible when diagnosed with
infiltrating mammary or ductal adenocarcinoma, were
negative for BRCA1 and BRCA2 mutations, and had a
sister with BC. The mutation screening strategy was
similar for all the clinics. The full coding sequences and
the exon-intron junctions of the BRCA1 and BRCA2 genes
were screened for mutations, based on pre-screening
(Denaturing High-Performance Liquid Chromatography
(dHPLC), High-Resolution Melting (HRM) or Enhanced
Mismatch Mutation Analysis (EMMA)) and sequencing.
For a subset of the index cases; large rearrangements were
screened by large cDNA sequencing, Multiplex Ligation-
dependent Probe Amplification (MLPA), Quantitative
Multiplex PCR of Short Fragments (QMPSF), Quantitative
PCR (qPCR), Quantitative PCR High Resolution Melting
(qPCR HRM), EMMA or dedicated array Comparative
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Genomic Hybridization (array CGH). Sisters with infiltrat-
ing mammary adenocarcinoma or in situ ductal carcin-
oma, regardless of their age at diagnosis, were eligible. If
the index case had more than one affected sister, all were
approached. Two types of controls were included: unre-
lated controls and unaffected sisters. The unrelated con-
trols were selected among the unaffected friends and/or
colleagues of the cases. The year of birth of controls was
matched to that of the corresponding case (+/− 3 years).
The parents, brothers and unaffected sisters were also
contacted, when possible.
Geneticists of family cancer clinics identified index cases
and invited them to participate in GENESIS by referring
them to the CC. Each family cancer clinic invited index
cases to participate in the study by letter (retrospective
index cases with a molecular diagnosis performed between
2003 and 2007) or during consultations informing patients
of their BRCA1/2 negative results (prospective index
cases). The CC organized the inclusion of index cases and
of their relatives and unrelated controls. The index case
then sent a response coupon to the CC to obtain the
complete study file including a detailed information letter
and a consent form to be completed. Subjects were in-
cluded in the study when they sent back their signed con-
sent, with the possibility of a telephone contact with a
member of the CC team and/or a genetic consultation for
additional information. The index case contacted her sis-
ters (affected and unaffected), parents and brothers, and
unrelated unaffected friends or colleagues and gave them
an information letter and response coupon. After their
agreement, the CC sent them the study file including the
detailed information letter and the consent form. Again,
relatives and unrelated subjects were included in the study
when they sent back their signed consent. The CC orga-
nized the collection of blood samples from the index case
and other participants by sending them a prescription for
blood sampling, a letter for the medical analysis laboratory
or the nurse who took the blood sample, and appropriate
prepaid packaging for dispatch of the samples directly to
the biological resource center at the Centre Léon Bérard
(Lyon, France).
The study was examined by the appropriate committees:
ethics (CCP Ile-de-France III, 3 October 2006, agreement
no. 2373) and by the data protection agency (CNIL, 22
May 2006, agreement no. 1170775), all of which approved
the study.
Data collected
All patients (index cases and affected sisters) and con-
trols completed a questionnaire on environmental, life-
style and reproductive factors and family history of
cancer. This self-report questionnaire contained de-
tailed questions concerning demographic data, alcohol
and tobacco consumption, pregnancies, breastfeeding,
contraception, hormone replacement, physical activity,
personal medical history and exposure to irradiation at
work and for medical purposes and pedigree, with de-
tailed information on medical history for each first- and
second-degree relative.
Mammograms taken at the time of diagnosis or one to
three years before diagnosis for the cases and most recent
mammography for the controls and unaffected sisters at
inclusion were collected. Craniocaudal and medio-lateral
oblique views of both breasts were digitized. A VIDAR
DiagnosticPro Advantage scanner, with a resolution of
570 dpi, was used to record the information required for
quantitative calculations of mammary density. The images
obtained were recorded and the identity of the participant
was erased from images with Adobe® Photoshop® software.
The incidence and date of the mammograms were re-
corded on the images.
Blood samples were collected from index cases, affected
and unaffected sisters and controls. Viable lymphocytes
from index cases were frozen if this had not already been
done by the laboratory having carried out BRCA1/2 ana-
lyses. Part of each blood sample was frozen, while the rest
was processed in order to obtain plasma, serum, and
lymphocyte pellets, all of which were then frozen. DNA
was subsequently extracted using the AutopureLS Instru-
ment (Qiagen).
No systematic collection of tumor specimens has been
performed. However, pathology reports and information
of sample storage conditions and location for mammary
tumors have been collected and are being coded and
computerized. This information will facilitate access to
the tumor samples for specific projects to come.
Study power
These data will be used to study the missing heritability of
BC by taking into account environmental factors. The
power of the study depends on the study design and strat-
egy employed for detecting BC susceptibility alleles. For in-
stance, SNP genotyping, mutation screening of candidate
genes or whole exome sequencing may be undertaken in all
subjects or specific subset of participants, since stratifying
data on endophenotypes may help decreasing genetic het-
erogeneity. Interaction effects according to the genes under
study may also be investigated. A “simple” power calcula-
tion showed that a genetic association with an amplitude of
3 (relative risk associated with a susceptibility genotype)
sought by a candidate gene approach in a case-control
study design can be identified with a power of 80 %
(alpha = 0.05) for allelic frequencies greater than 0.5 %
for a dominant inheritance and greater than 10 % for a
recessive inheritance. The power will decrease with
decreasing risk amplitude if the study eligibility cri-
teria lead to an underrepresentation of high-risk fam-
ilies. A priori power calculations are challenging and
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will depend on the hypotheses and models used (single
SNP analyses, gene pathway-based approaches, single
environmental/lifestyle factor, exposure profiles with
or without interaction…).
Results
Inclusion of participants started in February 2007 and
ended in December 2013. Description of the GENESIS
population is based on data available on 17 November
2014. Thus, the population may increase slightly when
residual signed inform consents are received by the CC.
Figure 1 shows the cumulative number of index cases
over the time-course of inclusion, both for retrospective
and prospective inclusions.
2543 patients qualified according to the study criteria
were listed and invited to participate by 26 centers. 1669
women sent back a reply coupon to the CC for complete
information about the study and 1315 agreed to participate
(i.e. 52 % of patients invited). 539 additional cases, invited
by 16 centers without being listed beforehand and meeting
the inclusion criteria returned a reply coupon and 406 of
them agreed to participate and were therefore included. A
total of 1721 patients were included, 1483 of whom had at
least one living sister affected by BC and potentially able to
participate in the study, and 238 of whom had no living
affected sister. Since the participation rate was not very
high, the representativeness of the included cases could be
questioned. Birth year, age at diagnosis and year of diagno-
sis were compared in the eligible population (631 index
cases) of the Institut Curie clinic where the information
was available. The characteristics of eligible index cases
and the characteristics of index cases included were similar,
i.e. 1948, 50 years and 1998 on average for birth year, age
at diagnosis and year of diagnosis, respectively. Thus, we
can be confident that the population of index cases is
representative of the targeted population.
98 % of index cases completed the epidemiological ques-
tionnaire and provided a blood sample; 68 % were able to
provide mammograms. The information on mammograms
was extracted from the epidemiological questionnaire. The
collection of mammograms is still on-going since many are
kept in the care centers where the women were treated for
their cancer (cf. Table 1). Table 2 shows that all index cases
included were on average 59 years old at inclusion (mini-
mum (min): 31 years old; maximum (max): 90 years old),
were born in 1950 (min: 1918; max: 1977) and were
49.7 years old at the BC diagnosis (min: 20 years old; max:
80 years old). The mean interval between the date of diag-
nosis and the date of inclusion was 9.3 years (min: 0 year;
max: 48 years).
This interval has an effect on the familial phenotype of
the index cases. 32 % of the index case families had 3 or
more cases of BC when the interval was greater than
10 years; this percentage decreases to 26 % when the inter-
val was less than 10 years. This difference is mostly due to
a longer survey of the families. When the follow-up of the
family members was censured at the year of diagnosis of
the index case, the percentage of index case families with 3
or more BC cases was 24 % when the interval was greater
than 10 years and 23 % when it was less than 10 years.
Thus, ascertainment by familial phenotype criteria appears
constant over time.
Of the 5095 sisters and controls invited by the index
cases and identified through the list of invitations sent
back by the index case, 2518 women agreed to partici-
pate, i.e. 685 sisters with BC (57 %), 541 unaffected sis-
ters (54 %) and 1292 controls (45 %). An extra 141
affected sisters, 58 unaffected sisters and 127 controls,
not previously listed in the index cases’ invitation list,
agreed to participate. Thus a total of 826 affected sisters,
599 unaffected sisters and 1419 controls were included.
98 % of the affected sisters and 99 % of the unaffected
sisters and controls completed the epidemiological ques-
tionnaire, and 97 % of the sisters and 96 % of the controls
provided a blood sample. 66 % of the affected sisters pro-
vided mammograms, a percentage similar to that of the
index cases, again because many of the mammograms are
kept in the care centers where the sisters with BC were
treated for cancer. The percentage was higher for the un-
affected sisters and the controls: 84 % and 91 %, respect-
ively (cf. Table 1). The mean ages at diagnosis and at
inclusion of the affected sisters were slightly higher than
those of the index cases, i.e. 51.4 and 59.5 years, respect-
ively, with therefore a slight decrease in the interval
between diagnosis and inclusion (8.1 years vs 9.3 years).
On average, the unaffected sisters were two years younger
than the index cases and the controls three years younger
(cf. Table 2).
Our target of recruiting 1000 sibpairs, based on power
calculations, was not reached. Among the 1483 index
cases with at least one sister alive and with BC, 696 had
at least one affected sister included (47 %). A total of
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Fig. 1 Cumulative number of index case inclusions over time. Legend:
Index cases with retrospective molecular diagnosis.
Index cases with prospective molecular diagnosis
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788 affected sisters agreed to participate. The size of the
sibships with participating affected sisters varied from 2
to 5 (cf. Table 3). Of the 696 sibships with at least two
affected sisters included, 678 completed the epidemio-
logical questionnaires, 669 provided blood samples and
362 provided mammograms. The absolute mean differ-
ence in the ages at diagnosis within sibpairs was 5.7 years
(Standard Deviation (SD): 8.2 years).
Since the controls were supposed to be either a friend
or a colleague of an index case, the representativeness
of this group is questionable in terms of family history
of cancer. Indeed, friends or colleagues may have par-
ticipated because they have a “strong” family history of
cancer. This bias might lead to an underestimate of the
effect of genetic factors. Therefore, we analyzed the
pedigree of the 1411 unrelated controls by comparing
the cancer incidences in these pedigrees (first degree of
relationship) to the national incidences using SAS 9.3
software (SAS Institute, Cary, NC) and the estimated
national cancer incidences from 1975 to 2005 [22]. We
observed a slight increased incidence of cancer within
control families for all sites (Standardized Incidence
Ratio (SIR): 1.11 95%CI: 1.02–1.22), for breast cancer
(SIR: 1.21 95%CI: 1.04–1.39) and for ovarian cancer
(SIR: 1.16 95%CI: 0.73–1.76) and this should be taken
into account in the further analyses.
Discussion
The GENESIS study is a unique national resource to study
the missing heritability of BC. This is a large study includ-
ing over 6000 participants, and the biological, clinical and
epidemiological data collected are detailed and complete.
The rate of agreement to participate was moderate for
each participant category, around 50 %. However, the con-
straint of asking the index cases to contact the other par-
ticipants impaired assessment of the true agreement rates
as for these people we relied on a list completed by the
index cases. Indeed, people not listed beforehand were in-
cluded (more than 11 % of the inclusions). Even though
we have full confidence in the representativeness of the
population of the included index cases and controls, it
may be more effective in future studies to contact relatives
and other participants directly.
Even though part of the study was prospective, most
index cases and their affected sisters were prevalent cases
(only 5.5 % were included in the calendar year of their BC
diagnosis or in the following year). This has to be taken
into account when seeking for BC susceptibility genes in
order to avoid false conclusion. For instance, identified
genes could be in fact involved in survival; conversely, one
could miss BC susceptibility genes that are also involved
in poor prognosis. Hence, for future studies using this
resource, a comparison between pseudo-incident cases
(interval between diagnosis and interview less than 5 years,
for example) and prevalent cases will be useful.
The unrelated controls were matched to the corre-
sponding index cases on the basis of the year of birth
(+/− 3 years) to simplify the index cases’ task of inviting
controls. However, because the large majority of index
cases were included prospectively, their invited controls
had survived without BC years after the index cases’
year of diagnosis. This may therefore result in bias to-
ward the alternative even after censuring controls at
the index cases’ age at diagnosis. To avoid such bias,
depending on the question under study, the controls
could be matched either to the index case’s year of
birth or age at BC diagnosis. The latter option should
be avoided when a cohort effect is observed for the var-
iables under study.
The eligibility criteria of GENESIS did not exclude
patients carrying a mutation in “clinically actionable”
susceptibility genes other than BRCA1 and BRCA2. In
France, PALB2 testing was introduced in the clinical
practices in July 2015; therefore PALB2 status in GEN-
ESIS index cases was not available at the time of inclu-
sion. Subsequently, a case-control study performed in
French BC families and including the first 40 % of the
recruited GENESIS index cases has shown that PALB2
truncating mutation are found in 0.36 % of the familial
cases [23]. Whole-exome and whole-genome sequencing
projects are also ongoing on a subset of the GENESIS
population, as well as targeted sequencing of a panel of
high- to moderate-risk genes for more than 2000 GENESIS
Table 1 Available data in GENESIS per type of participant
Type of participant Signed consent form Completed questionnaire Blood sample At least one mammogram
performeda
At least one mammogram
collected
N N (%) N (%) N N (%)
Index case 1721 1682 (98 %) 1695 (98 %) 1721 1169 (68 %)
Affected sister 826 807 (98 %) 805 (97 %) 826 546 (66 %)
Unaffected sister 599 592 (99 %) 582 (97 %) 589 493 (84 %)
Control 1419 1411 (99 %) 1360 (96 %) 1322 1201 (91 %)
Total 4565 4492 (98 %) 4442 (97 %) 4458 3409 (76 %)
N, number; %, percentage, abased on questionnaire information for unaffected women
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Table 2 Characteristics of the GENESIS population according to the type of participant
Type of participant Year of birth Age at breast cancer diagnosis (years) Age at inclusion (years) Interval between diagnosis and inclusion
By class
≤4 years 5-9 years ≥10 years
N mean (SD) [min, max] mean (SD) [min, max] mean (SD) [min, max] mean (SD) N (%) N (%) N (%)
Index case 1682 1950 (9.3) [1918, 1977] 49.7 (9.3) [20, 80] 59.0 (9.3) [31, 90] 9.3 (7.4) 559 (33 %) 480 (29 %) 643 (38 %)
Affected sister 807 1949 (9.0) [1926, 1978] 51.4 (8.7) [27, 77] 59.5 (8.8) [30, 83] 8.1 (6.4) 297 (37 %) 249 (31 %) 258 (32 %)
Unaffected sister 592 1952 (9.3) [1926, 1978] 57.0 (9.2) [30, 84]
Control 1411 1953 (10.0) [1926, 1991] 55.7 (9.9) [19, 83]











participants. Genes under investigation includes, among
others, ATM, CHEK2, RAD51 paralogs and those included
in panels used by the French diagnosis laboratories for re-
search purpose (Lesueur et al. personal communication).
Subjects carrying a mutation in one of these genes will be
therefore identifiable for subsequent studies.
The low number of large families for which nearly all
first-degree relatives have been recruited might be a limi-
tation for powerful co-segregation analyses. However, in
order to validate new potential BC susceptibility genes, it
will be possible to use additional large sample set thanks
to the GGC families’ recruitment or through participation
to other international high-risk family studies.
Conclusions
The identification of new BC susceptibility genes will
clearly have implications for the management of women
at risk. It will enable adaptation of the follow-up of these
women according to risk assessments based on new
tests. If the risk is considered high, early and regular
MRI-based screening could be offered.
The identification of new genes should improve our
understanding of the origin of a proportion of BC spor-
adic cases and should make it possible to optimize the
management of these cases’ relatives.
Finally, an understanding of the biological functions of
these genes and their interactions with environmental
factors may reveal new possibilities for the prevention
and treatment of BC, the incidence of which is continu-
ing to increase in Western populations.
The GENESIS study will be an asset for ongoing molecu-
lar studies aiming at identifying new BC susceptibility
genes, and such studies using this resource have already
started (e.g. [23–25]). GENESIS resource also contributes
to international consortia like COMPLEXO (COMPLexity
of EXOme) [26].
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at least 2a 696 678 669 362
exactly 2a 616 600 592 324
exactly 3a 69 67 67 34
exactly 4a 10 10 9 4
exactly 5a 1 1 1 0
aWhether the women are index cases or affected sisters
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Paris: F. Cornélis; Hôpital Tenon, Paris: A. Fajac; GH Pitié Salpétrière et Hôpital
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Villejuif: A. Chompret†, O. Caron).
†: deceased prematurely
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